Skip to search formSkip to main contentSkip to account menu

AIN 457

Known as: AIN-457, AIN457 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Asthma stratification efforts have predominantly focused on subgroups defined by levels of circulating and sputum eosinophils. In… 
Highly Cited
2016
Highly Cited
2016
We have previously demonstrated that interleukin-17A (IL-17) producing T helper 17 cells are significantly elevated in blood and… 
Review
2016
Review
2016
ABSTRACT Introduction: Ankylosing spondylitis (AS) is a chronic immune-mediated disease characterised by inflammation and new… 
Review
2016
Review
2016
Summary Secukinumab (also known as AIN-457) is a human monoclonal antibody targeting IL-17A, which has been recently FDA-approved… 
Highly Cited
2014
Highly Cited
2014
The family of interleukin 17 receptors (IL17Rs), subtypes IL17RA‐IL17RE, is targeted by the group of pro‐inflammatory IL17… 
2013
2013
To the Editor: Within the lung the T-helper cell interleukin (IL)-17 (also referred to as IL-17A) is recognised as one of the… 
2013
2013
Background Monoclonal antibodies (mAbs) comprise a large and important class of therapeutic biologicals with the potential for… 
Review
2011
Review
2011
This overview of 25 monoclonal antibody (mAb) and 5 Fc fusion protein therapeutics provides brief descriptions of the candidates… 
Review
2011
Review
2011
Abstract Anti-cytokine therapies, including the anti-TNF-α antibody-based therapies, have largely transformed the management of… 
Highly Cited
2010
Highly Cited
2010
A human antibody to interleukin-17A is well tolerated and may be effective in the treatment of psoriasis, rheumatoid arthritis…